deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 8-arm NCT02126579

Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists (MEL60)

Open Label, Randomized, Phase I/II Study of a Long Peptide Vaccine Plus TLR Agonists for Resected Stage IIb-IV Melanoma. (MEL60)

Sponsor: Craig L Slingluff, Jr

Conditions Melanoma Metastatic Melanoma Mucosal Melanoma
Interventions IFA Peptide Vaccine (LPV7) + Tetanus peptide PolyICLC Resiquimod
Updated 14 times since 2017 Last updated: Feb 2, 2024 Started: May 1, 2014 Primary completion: Nov 20, 2019 Completion: May 5, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02126579, this PHASE1/PHASE2 trial focuses on Melanoma and Metastatic Melanoma and remains completed. Sponsored by Craig L Slingluff, Jr, it has been updated 14 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Oct 2017 · 8 months · monthly snapshot~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshot~Jun 2018 – ~Jul 2019 · 13 months · monthly snapshot~Jul 2019 – ~Nov 2019 · 4 months · monthly snapshot~Nov 2019 – ~Aug 2020 · 9 months · monthly snapshot~Aug 2020 – ~Dec 2020 · 4 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Dec 2022 · 23 months · monthly snapshot~Dec 2022 – ~Dec 2023 · 12 months · monthly snapshot~Dec 2023 – ~Mar 2024 · 3 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 23 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Mar 2024 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Dec 2023 — Mar 2024 [monthly]

    Completed PHASE1_PHASE2

    Status: Unknown Status → Completed

  5. Dec 2022 — Dec 2023 [monthly]

    Unknown Status PHASE1_PHASE2

    Status: Active Not Recruiting → Unknown Status

▶ Show 9 earlier versions

  1. Jan 2021 — Dec 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Aug 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Nov 2019 — Aug 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Jul 2019 — Nov 2019 [monthly]

    Recruiting PHASE1_PHASE2

  6. Jun 2018 — Jul 2019 [monthly]

    Recruiting PHASE1_PHASE2

  7. Oct 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  8. Feb 2017 — Oct 2017 [monthly]

    Recruiting PHASE1_PHASE2

  9. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

May 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Craig L Slingluff, Jr
  • University of Virginia
Data source: University of Virginia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations